Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1Bulbo-Spinal Atrophy, X-Linked 1Adenocarcinoma 1

Interventions

Specimen Handling 4Biopsy 4Magnetic Resonance Spectroscopy 3vactosertib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1pegamotecan 1neratinib 1ipatasertib 1fludarabine phosphate 1binimetinib 1aldesleukin 1X-Rays 1Trastuzumab 1Taxes 1Surveys and Questionnaires 1Phantoms, Imaging 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1NUC-1031 1N-acetylcochinol-O-phosphate 1Ipilimumab 1Interleukin-2 1IL32 protein, human 1Gemcitabine 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Neoplasm Metastasis × 5'-ACCaagtttcttcAGC-3' × Clear all
NCT01337518 2012-12-18

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Enzon Pharmaceuticals, Inc.

Phase 1 Suspended
150 enrolled
Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡